NCT02954653 - A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 28, 2016

Primary Completion Date

December 5, 2017

Study Completion Date

December 5, 2017

Conditions

Acute Myeloid Leukemia

Interventions

BIOLOGICAL

PF-06747143

PF 06747143 is a humanized IgG1 monoclonal antibody (mAb) that is an antagonist of CXCR4.

DRUG

Cytarabine

100-200 mg/m2 continuous infusion for 7 days)

DRUG

Daunorubicin

60-90 mg/m2 daily for 3 days

DRUG

Azacitidine

75 mg/m2 sub-cutaneous or intravenous for 7 days)

DRUG

Decitabine

20 mg/m2 continuous intravenous infusion for 5 days in a 4-week schedule

Trial Locations (4)

Wake Forest Baptist Health, Winston-Salem

The University of Chicago Medical Center, Chicago

The University of Arizona Cancer Center-North Campus, Tucson

Banner-University Medical Center Tucson, Tucson